Back to Journals » Therapeutics and Clinical Risk Management » Volume 11

Patient considerations in the management of ulcerative colitis – role of vedolizumab

Authors Kothari M, Mudireddy P, Swaminath A

Received 18 January 2015

Accepted for publication 10 June 2015

Published 19 August 2015 Volume 2015:11 Pages 1235—1242


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Editor who approved publication: Professor Garry Walsh

Video abstract presented by Megha Kothari

Views: 779

Megha Kothari, Prashant Mudireddy, Arun Swaminath

Division of Gastroenterology and Hepatology, Lenox Hill Hospital-NSLIJ, New York, NY, USA

Abstract: Ulcerative colitis (UC) is a subtype of inflammatory bowel disease which causes inflammation of the large intestine and affects approximately 7.6–24.6 per 100,000 persons. The therapeutic goal for UC patients is inducing remission, maintaining remission, and ideally, obtaining mucosal healing. Vedolizumab, approved by the US Food and Drug Administration in May 2014 for the treatment of moderate-to-severe UC and Crohn’s disease, is a newly developed anti-integrin therapy. This review focuses on the preclinical development of vedolizumab and data from early trials, and details the results of the landmark trails that led to its approval in the USA with a specific focus on the management of UC. Additionally, data on safety and the current UC management protocols are also discussed.

Keywords: inflammation, mucosal healing, remission, immunomodulator drugs, infliximab, ulcerative colitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]